Scilex Holding Company Research and Development Expense
Scilex Holding Company (SCLX) reported Research and Development Expense of $3.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Scilex Holding Company research and development expense for the quarter ending 2026-06-30 was $3.34M, a 46.08% decline year-over-year.
- Scilex Holding Company research and development expense for the quarter ending 2026-03-31 was $3.21M, a 30.70% increase year-over-year.
- Scilex Holding Company research and development expense for the quarter ending 2025-12-31 was $8.17M, a 274.68% increase year-over-year.
- Scilex Holding Company research and development expense for the quarter ending 2025-09-30 was $3.90M, a 65.99% increase year-over-year.
- Scilex Holding Company research and development expense for fiscal 2025 was $20.71M, a 114.81% increase from fiscal 2024.
- Scilex Holding Company research and development expense for fiscal 2024 was $9.64M, a 24.36% decline from fiscal 2023.
- Scilex Holding Company research and development expense for fiscal 2023 was $12.75M, a 40.78% increase from fiscal 2022.
- Scilex Holding Company research and development expense for fiscal 2022 was $9.05M, a 1.60% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.34M 10-Q · filed 2026-08-14 | $6.55M 10-Q · filed 2026-08-14 | $14.71M derived: sum of 3 quarters · filed 2026-08-14 | $18.61M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.21M 10-Q · filed 2026-05-20 | $11.38M derived: sum of 2 quarters · filed 2026-05-20 | $15.28M derived: sum of 3 quarters · filed 2026-05-20 | $21.46M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $8.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $12.07M derived: sum of 2 quarters · filed 2026-04-10 | $18.25M derived: sum of 3 quarters · filed 2026-08-14 | $20.71M 10-K · filed 2026-04-10 |
| 2025-09-30 | $3.90M 10-Q · filed 2025-11-14 | $10.09M derived: sum of 2 quarters · filed 2026-08-14 | $12.54M 10-Q · filed 2025-11-14 | $14.72M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $6.19M 10-Q · filed 2026-08-14 | $8.64M 10-Q · filed 2026-08-14 | $10.82M derived: sum of 3 quarters · filed 2026-08-14 | $13.17M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.46M 10-Q · filed 2026-05-20 | $4.64M derived: sum of 2 quarters · filed 2026-05-20 | $6.99M derived: sum of 3 quarters · filed 2026-05-20 | $8.99M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $4.53M derived: sum of 2 quarters · filed 2026-04-10 | $6.53M derived: sum of 3 quarters · filed 2026-04-10 | $9.64M 10-K · filed 2026-04-10 |
| 2024-09-30 | $2.35M 10-Q · filed 2025-11-14 | $4.35M derived: sum of 2 quarters · filed 2025-11-14 | $7.46M 10-Q · filed 2025-11-14 | $10.20M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $2.00M 10-Q · filed 2025-08-13 | $5.11M 10-Q · filed 2025-08-13 | $7.85M derived: sum of 3 quarters · filed 2025-08-13 | $11.92M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $3.11M 10-Q · filed 2025-05-14 | $5.84M derived: sum of 2 quarters · filed 2025-05-14 | $9.91M derived: sum of 3 quarters · filed 2025-05-14 | $13.12M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $6.81M derived: sum of 2 quarters · filed 2025-03-31 | $10.01M derived: sum of 3 quarters · filed 2025-03-31 | $12.75M 10-K · filed 2025-03-31 |
| 2023-09-30 | $4.07M 10-Q · filed 2025-01-17 | $7.28M derived: sum of 2 quarters · filed 2025-01-17 | $10.01M 10-Q · filed 2025-01-17 | $12.61M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $3.20M 10-Q · filed 2024-08-13 | $5.94M 10-Q · filed 2024-08-13 | $8.54M derived: sum of 3 quarters · filed 2024-08-13 | $9.77M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $2.74M 10-Q · filed 2024-05-13 | $5.33M derived: sum of 2 quarters · filed 2024-05-13 | $6.57M derived: sum of 3 quarters · filed 2024-05-13 | $9.16M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $3.83M derived: sum of 2 quarters · filed 2024-03-12 | $6.42M derived: sum of 3 quarters · filed 2024-03-12 | $9.05M 10-K · filed 2024-03-12 |
| 2022-09-30 | $1.24M 10-Q · filed 2023-11-14 | $3.83M derived: sum of 2 quarters · filed 2023-11-14 | $6.46M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $2.59M 10-Q · filed 2023-08-11 | $5.22M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $2.63M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $9.20M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $9.96M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |